Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Clinical trial NCT04560322 · RECRUITING

Trial details

NCT number: NCT04560322
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Start date: 2020-10-19
Primary completion: 2028-03-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.